A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model
Abstract Background The global burden of hepatitis B virus (HBV) infection in terms of morbidity and mortality is immense. Novel treatments that can induce a protective immune response are urgently needed to effectively control the HBV epidemic and eventually eradicate chronic HBV infection. Methods...
Main Authors: | Yunlong Hu, Li Tang, Zhengyu Zhu, He Meng, Tingting Chen, Sheng Zhao, Zhenchao Jin, Zhulin Wang, Guangyi Jin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-020-02275-2 |
Similar Items
-
Investigation of HBV DNA in HBsAg positive patients
by: Nihal Secil Bati, et al.
Published: (2017-12-01) -
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
by: Romina Salpini, et al.
Published: (2020-02-01) -
Is Quantitative HBsAg Measurement a Reliable Substitute for HBV DNA Quantitation?
by: Mohammad Reza Mahdavi, et al.
Published: (2015-07-01) -
Using the Quantitative Determination of HBsAg to Monitor the Natural History of Chronic HBV-Infection
by: I.A. Zaitsev
Published: (2015-09-01) -
Using the Quantitative Determination of HbsAg to Monitor Antiviral Therapy of Chronic HBV-Infection
by: I.A. Zaitsev
Published: (2015-04-01)